
    
      The study consisted of:

        -  a 4- to 6-month screening/baseline period

        -  a 12-month (up to Day 360+/-5 days) double-blind treatment period starting on Day 1

        -  a 2-month follow-up period (up to Day 420+/-5 days)
    
  